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The aim of this study was to investigate the effects of metastasis-associated protein 1 (MTA1) deficiency during
angiogenesis of pulmonary alveolar capillaries in mice and to determine the molecular mechanisms involved.
The expressions of MTA1, CD34, vascular endothelial growth factor (VEGF), alpha smooth muscle actin (a-SMA),
and HIF-1a were analyzed in the lungs of MTA1-knockout (KO) and wild-type mice at embryonic day 18.5 and
2 months by quantitative PCR, immunoblotting, and immunohistochemistry. The morphological changes were
investigated during pulmonary alveolar capillary formation. The heart weight/body weight (HW/BW) ratio and
the size of the right ventricular wall cardiomyocytes were also measured. Regulation of MTA1 on HIF-1a was
determined in vitro.
MTA1 deficiency reduced the number of pulmonary alveolar capillaries compared to the wild-type mice. MTA1KO mice exhibited a decreased expression of HIF-1a and VEGF in the lungs. The retarded growth of the MTA1KO mice was also noticed during the first week after birth. Accordingly, MTA1 deficiency resulted in increased
infant mortality. In surviving adult mice, MTA1 deficiency induced myocardial hypertrophy, highlighted by an
increased heart weight/body weight ratio and larger cardiomyocytes. In cultured cells, HIF-1a and VEGF levels were significantly upregulated upon MTA1 overexpression, suggesting a close relationship between all 3
molecules.
MTA1 participates in the formation of pulmonary capillaries via stabilization of HIF-1a. This finding sheds new
light on the function of MTA1 in lung development, opening new avenues for the diagnosis/treatment of related pulmonary diseases.
Mice, Knockout • Neovascularization, Physiologic • Persistent Fetal Circulation Syndrome
https://www.medscimonit.com/abstract/index/idArt/905992
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Background
Metastasis-associated protein 1 (MTA1), a member of the nucleosome remodeling and decarboxylation complex (NuRD)
family, has a profound role in pathological and physiological processes, and is highly expressed in mouse tissues and
organs [1–3]. MTA1 regulates the expression of target genes
due to its corepressor or coactivator activity [4]. In addition,
MTA1 influences biological functions by modifying the stability of target proteins via deacetylation of non-histone proteins
such as hypoxia-inducible factor 1-alpha (HIF-1a) by MTA1/histone deacetylases (HDACs) [5]. MTA1 expression correlates well
with tumor angiogenesis, as well as with HIF-1a and its target
genes such as vascular endothelial growth factor (VEGF) [5–7].
Previous research has shown that specific HDACs induce angiogenesis and influence the stability of HIF-1a in mice [8,9].
Vascular development in the lungs is a complex, multistep
process controlled by several factors, including HIF-1a and
VEGF [10–12]. Notably, pulmonary vascular endothelial cells
play a crucial role in regulating the pulmonary vascular system, and in maintaining barrier function and integrity of alveolar capillary membranes [13]. These cells, as well as other
cell types in the lungs, express high levels of VEGF, which has
been shown to be essential during fetal lung development,
a process critically dependent on oxygen tension and angiogenesis [14]. Accordingly, administration of VEGF initiates the
process of vessel formation [15,16]. Transcription of VEGF is
regulated by HIF-1a, a target of MTA1 [17,18]. In addition, increased HIF-1a expression and its nuclear translocation are
associated with pronounced angiogenesis [13,19]. These observations suggest that expression of HIF-1a and VEGF is integral to the process of angiogenesis. Although HDACs induce
angiogenesis and influence the levels of HIF-1a in mice [8,9],
the role of MTA1 and HIF-1a in promoting angiogenesis during lung development remains unknown.
The present study was designed to determine the contribution of MTA1 and its downstream pathways during pulmonary vascular development in MTA1-knockout (KO) mice. Our
results suggest that MTA1 facilitates the angiogenesis of pulmonary alveolar capillaries by stabilizing HIF-1a, opening the
possibility of new diagnosis and treatments for related pulmonary diseases.

Material and Methods
Animals and tissue collection
MTA1-KO mice were kindly provided by Dr. Rakesh Kumar’s
laboratory and were handled according to the Care and Use
of Laboratory Animals guidelines of Fourth Military Medical
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University. The animals were maintained under a 12-h light/12-h
dark cycle with ad libitum access to water and chow diet. Before
sacrificing and tissue collection, animals were fasted for 4 h.
Tissues were collected and either directly ﬁxed in 4% formaldehyde to produce parafﬁn sections or flash-frozen in liquid nitrogen followed by storage at –80°C for further protein
and mRNA analysis. The age of the fetus was determined relative to the date on which the vaginal plug was found, which
was set to 0.5 E.
Cell culture and transfection of an MTA1 overexpression
vector
293T cells were grown in medium supplemented with 10% fetal bovine serum and 1× antibiotic-antimycotic solution in a
humidified incubator with 5% CO2 at 37°C. Cell culture medium
and additives were obtained from Gibco (Invitrogen). MLE-12
cells were obtained from the Cell Center of Fudan University
(China). Cells were cultured in HITES (hydrocortisone, insulin,
transferrin, estrogen) medium (Gibco) supplemented with 10%
fetal bovine serum (FBS) and 2 mM glutamine at 37°C under
conditions of 5% CO2. Transient transfections were performed
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Antibodies and reagents
Sources of antibodies were as follows: MTA1 (D40D1) XP® rabbit mAb (#5647, Cell Signaling Technology); CD31 (PECAM-1)
(D8V9E) XP® rabbit mAb (#77699, Cell Signaling Technology);
rabbit anti-CD34 (BA0532, Boster Bio-Technology Co., LTD);
rabbit anti-VEGF (BA0407, Boster Bio-Technology Co., LTD);
ERG (A7L1G) Rabbit mAb (#97249, Cell Signaling Technology);
rabbit anti-HIF-1a/HIF1A (PB0245, Boster Bio-Technology Co.,
LTD); rabbit anti-alpha smooth muscle actin (a-SMA) (ab5694,
Abcam); and b-actin (Abcam). MTA1-pIRES2-EGFP was from
Dongao-Technology Co., LTD. Biotinylated rabbit anti-goat IgG
secondary antibody (K0675, Dako), streptavidin-horseradish
peroxidase (HRP) (K0675, Dako), and 3-3 diaminobenzidine
(DAB) (Dako) enzyme-substrate complexes were used for immunohistochemical staining. HRP-conjugated rabbit anti-goat
IgG (Sigma) was used for Western blot analysis.
Heart weight/body weight (HW/BW) ratio
At 8 weeks, mice were weighted and executed by cervical vertebrae luxation. The heart was taken out and washed with
normal saline to remove excess connective tissues and vessels. Bibulous paper was used to absorb any residual saline
on the samples before they were weighed and measured. A
Vernier caliper was employed to measure cardiomyocyte size.
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Immunohistochemistry

Table 1. Primers for real-time PCR.
Name

Direction

Sequences

MTA1

Forward
Reverse

5’-AGGAGGAAGAGGAGGAGGAGAATAT-3’
5’-GGCACCAGATCACATAGTTGTG-3’

ERG

Forward
Reverse

5’-GTGGGCGGTGAAAGAATATGG-3’
5’-CTTTGGACTGAGGGGTGAGG-3’

CD34

Forward
Reverse

5’-GATAATTGCCATTCCCATGC-3’
5’-CAGACTCCACCACCTTACTTGAC-3’

HIF-1a

Forward
Reverse

5’-AACAGTGACAAAAGACCGTA-3’
5’-ATGACTCCTTTTCCTGCTCT-3’

VEGF

Forward
Reverse

5’-GAGATGAGCTTCCTACAGCACAACA-3’
5’-GGAACATTTACACGTCTGCGGATCT-3’

b-actin

Forward
Reverse

5’-CGTTGACATCCGTAAAGACCTC-3’
5’-ACAGAGTACTTGCGCTCAGGAG-3’

Real-time polymerase chain reaction
Total RNA was extracted with TRIzol reagent (Invitrogen) and
reverse-transcribed to cDNA using the PrimeScript RT reagent
Kit (Takara) according to the manufacturer’s protocol. Primers
were synthesized by Sangon Biotech (Shanghai, China). All
primer sequences are provided in Table 1. Quantitative PCR
was performed using a 7500 Real-time PCR System and Power
SYBR MasterMix (Applied Biosystems) following the manufacturer’s instructions. Relative mRNA expression was calculated
using the 2–DDCt method with the Ct values normalized to b-actin as internal control.

Parafﬁn sections (4 μm) were placed on poly-L-lysine-coated glass slides and stained according to standard immunohistochemical procedures. Brieﬂy, after deparafﬁnization and
washing in PBS, the sections were covered with 3% hydrogen
peroxide in PBS for 15 min at room temperature to block endogenous peroxidase activity. The sections were blocked with
5% bovine serum albumin and incubated with primary antibodies against MTA1 (1: 50), HIF-1a (1: 100), VEGF (1: 200),
a-SMA (1: 100), ERG (1: 200) or CD34 (1: 200) in a humidified
chamber at 4°C overnight. After washing, the sections were
incubated with biotinylated goat anti-rabbit IgG (Boster BioTechnology Co., LTD) for 1 h at 37°C. PBS (pH 7.2) was used to
rehydrate the samples, followed by incubation with the avidin-biotinylated peroxidase complex for 45 min at 37°C. After
washing in PBS, peroxidase activity was revealed using DAB
according to the manufacturer’s instructions.
Red blood cell staining
After fixation, red blood cells were stained for hemoglobin using a pseudoperoxidase reaction with DAB. First, slides were
placed in 0.05% DAB, 1% imidazole 1 M, and 0.1% H2O2 in
50 mM Tris-HCl buffer (pH 7.4) for 10 min in a dark environment. They were then washed with demineralized water and
counterstained using Harris hematoxylin for 2 min according to the manufacturer’s instructions. Finally, the slides were
rinsed with demineralized water and washed in running tap
water to improve staining, dehydrated, cleared, and mounted.

Protein preparation and western blot analysis
Transmission electron microscopy
Total protein was extracted from tissues using RIPA buffer containing phenylmethylsulfonyl fluoride. After protein separation
on 10% SDS-polyacrylamide gels and transfer to nitrocellulose, membranes were blocked with 5% (m/V) non-fat milk in
0.05% Tween-20/phosphate-buffered saline (PBS-T). The membranes were then washed (3×10 min) with PBS-T and further
incubated with primary antibodies against MTA1 (1: 1000),
HIF-1a (1: 200), VEGF (1: 200), CD34 (1: 200), ERG (1: 1000),
AQP5 (1: 1000), SPB (1: 1000), b-catenin (1: 1000), or b-actin
(1: 3000) for 1.5 h at 37°C. After additional washes, the membranes were treated with anti-goat IgG HRP-conjugated secondary antibody (1: 10,000) in 5% non-fat milk-PBS-T for 1 h
and washed again as above. Finally, an enhanced chemiluminescence system (Amersham Pharmacia) was used to develop
the blots. Exposure times ranged from 40 s to 15 min. Signal
intensities were semi-quantified and values were normalized
to those of loading controls. Relative expression is presented in arbitrary units.
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Transmission electron microscopy was performed as follows:
tissues were quickly removed and fixed with 2.5% glutaraldehyde, post-fixed in 1% osmium tetroxide in the same buffer
for 1 h and dehydrated in acetone for embedding in Araldite.
Semi-thin sections (thickness of 1 um) were stained with an
alkaline solution of toluidine blue. Ultrathin sections were contrasted with lead citrate and uranyl acetate, and examined
with an electron microscope.
Statistical analysis
Data are presented as mean ± standard error of the mean.
Student’s t-test and Mann-Whitney U test were used for parametric and nonparametric data, respectively. All statistical analyses were performed using GraphPad Prism V5.0 (GraphPad
Software). Statistical signiﬁcance was set at p<0.05.
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Figure 1. Expression of MTA1 in various tissues and organs of adult mice and during embryonic lung development. (A, B) MTA1 protein
and mRNA expression by Western blotting and real-time PCR, respectively, in different tissues of adult wild-type mice.
(C) immunohistochemical analysis demonstrates MTA1 expression in the lungs at E16.5, E18.5, and P1. (D) MTA1 protein
expression in the lungs at E16.5, E18.5, and P1. Scale bar, 50 μm. (D, E) A gradual, but significant decrease in the protein and
mRNA levels of MTA1 was observed in the lungs from E16.5 to P1. Actin controls in A and D were blotted in parallel gels with
the same amount of loading. n=6, * P<0.05, ** P<0.01, *** P<0.001.
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Figure 2. MTA1 deficiency increases infant mortality and impairs growth. (A) Postnatal mortality shows that over one-third of
homozygous MTA1-KO mice died within 7 days after birth compared to wild-type mice. (B, C) MTA1-deficient mice that
did survive exhibited retarded growth and markedly decreased body weight compared to wild-type mice. n=30, * P<0.05,
** P<0.01, *** P<0.001.
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Figure 3. MTA1-KO mice present cardiac hypertrophy. (A) Representative images of HE-stained MTA1-KO and wild-type cardiac
structures. Compared with wild-type animals, cardiomyocytes of MTA1-KO mice were bigger and hypertrophied (p<0.05).
(B) The HW/BW ratio was significantly higher in MTA1-KO than in wild-type mice at 8 weeks of age (p<0.05), indicating
MTA1 deficiency induced myocardial hypertrophy in adult mice. (C, D) The size of right ventricular cardiomyocytes was
significantly larger in MTA1-KO than in wild-type mice at 8 weeks of age (n=10), * P<0.05, ** P<0.01, *** P<0.001. (E) a-SMA
immunostaining highlights pulmonary artery wall thickening and hypertension in MTA1-KO mice (n=6). Scale bar, 50 μm.

Results

MTA1 deficiency increases infant mortality and retards
growth

MTA1 is abundantly expressed in mouse lung tissue
To determine the distribution of the MTA1 protein and its role
in mice, we examined the levels of MTA1 in different tissues
of mice by Western blot analysis. Our data indicate that MTA1
protein was present at high levels in the lungs, testis, and ovaries; at moderate levels in the brain, liver, mammary glands,
and kidneys; at low levels in the heart, stomach, colon, and
spleen; and could not be detected in the uterus (Figure 1A).
The levels of MTA1 in various tissues corroborated well with
MTA1 mRNA levels determined by real-time PCR (Figure 1B).
An immunohistochemical analysis indicated that MTA1 was
generally localized within cell nuclei (Figure 1C). We noticed a
gradual decrease in the protein and mRNA levels of MTA1 expression during development from embryonic day 16.5 (E16.5)
to postnatal day 1 (P1) in wild-type mice (Figure 1D, 1E). These
findings suggest that MTA1 is expressed at high levels in the
lung tissue, and the role of MTA1 in lung development was
examined in subsequent studies.

This work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

To investigate the function of MTA1 in mouse development,
we evaluated mice at E18.5 and P7, which gave an estimate
of postnatal mortality in the first week after birth. We found
that, compared to wild-type mice, over one-third of homozygous MTA1-KO mice died within the first 7 days after birth
(Figure 2A). However, some MTA1-KO mice did survive, exhibiting retarded growth and decreased body weight compared to wild-type littermates (Figure 2B, 2C). These observations suggest that MTA1 depletion increases infant mortality
and inhibits growth.
MTA1-deficient animals exhibit myocardial hypertrophy
and pulmonary arterial hypertension
To further determine the role of MTA1 in the lungs, we investigated the effect of MTA1 deficiency on cardiac structure, because pulmonary capillary damage could cause pulmonary hypertension. The HW/BW ratio is an established parameter for
evaluating cardiac structure. We report a significant increase
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Figure 4. MTA1-KO mice display reduced vascularization of the lungs. (A–C) HE and Heme staining demonstrate a significantly reduced
number of pulmonary capillaries and red blood cells in the lungs of MTA1-KO mice compared to wild-type animals. n=10,
Scale bar, 50 μm, *P<0.05, ** P<0.01, *** P<0.001. (D) Transmission electron micrograph showing a similar decrease in the
number of pulmonary capillaries () and red blood cells (RBC, ☆) at E18.5 and 2M in MTA1-KO mice. n=6, Scale bar, 5 μm.

in the HW/BW ratio in MTA1-KO compared to wild-type mice
at 8 weeks of age (p<0.05; Figure 3A, 3B). Accordingly, MTA1
deficiency might induce myocardial hypertrophy in the adult
mice due to a reduction of mature capillaries in pulmonary
alveoli. To analyze the cardiac structure in further detail, we
performed hematoxylin-eosin (HE) staining to calculate the
thickness of the right ventricular wall. Consistent with an increase in the HW/BW ratio, cardiomyocytes’ size was also significantly higher in MTA1-KO mice compared to wild-type mice
(Figure 3C, 3D). The observation that MTA1 deficiency induced
pulmonary artery wall thickening and pulmonary arterial hypertension was further validated by a-SMA immunostaining
(Figure 3E). These results further indicate that MTA1 deficiency leads to pulmonary hypertension and myocardial hypertrophy in adult mice.
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MTA1 deficiency impairs the formation of capillary beds
To evaluate if capillary beds were affected in the lungs of
MTA1-deficient mice, we used HE and Heme staining to assess
the status of pulmonary capillaries and red blood cells (RBC).
We noticed significantly fewer capillary beds and RBC in the
lungs of MTA1-KO animals compared to wild-type littermates
(Figure 4A–4C). This finding was confirmed at the E18.5 and
2M stage by transmission electron microscopy (Figure 4D).
Immunohistochemistry results indicated that the expression level of CD34 was decreased in the lung tissue of MTA1-KO mice at
E18.5 and 2M compared to the wild-type group (Figure 5A, 5B).
However, the percentages of ERG positive cells were similar
in the alveolar walls of wild-type and MTA1-KO mice at E18.5
and were increased significantly in the MTA1-deficient mice of
2M (Figure 5C). Accordantly, the same expression tendencies
at both the protein and mRNA levels were confirmed at the
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Figure 5. MTA1 deficiency impairs the formation of pulmonary capillary beds. (A, B) Immunohistochemistry results showed fewer
CD34-positive cells in the lungs of MTA1-KO animals compared to wild-type mice at E18.5 and 2M. n=10, Scale bar, 50 μm,
* P<0.05, ** P<0.01. (C) The percentages of ERG positive cells were similar in the alveolar walls of wild-type and MTA1KO mice at E18.5 but were increased significantly in the MTA1-deficient mice of 2M. n=10, Scale bar, 50 μm. (D) Western
blot analysis highlights the downregulation of CD34 in the lungs of MTA1-KO mice at E18.5 and 2M compared to wildtype animals. ERG levels were similar at E18.5 but increased significantly in the MTA1-deficient mice of 2M. (E, F) The same
expression tendencies of CD34 and ERG at mRNA levels were confirmed at the E18.5 and 2M stage by real-time PCR analysis.
n=10, * P<0.05.
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Figure 6. Regulation of HIF-1a expression by MTA1. (A, B) Real-time PCR and Western blot analysis results indicated that MTA1
correlates well with many lung development-related factors such as VEGF, AQP5, SPB, and b-catenin. (C, D) Western blot and
real-time PCR showed significant upregulation of HIF-1a and VEGF in 293T and MLE-12 cells overexpressing MTA1 36 h after
transfection. n=3, * P<0.05, ** P<0.01, *** P<0.001.

E18.5 and 2M stage by Western blot and real-time PCR analysis (Figure 5D–5F). These results indicate that MTA1 deficiency could reduce the number of mature capillaries in pulmonary alveoli, suggesting MTA1 is involved in the development
and maturation of pulmonary alveolar capillaries.

VEGF and induces angiogenesis. However, this pathway was
largely disrupted in the MTA1-KO mice, and results in the observed deficient formation of pulmonary capillaries.

Discussion

MTA1 deficiency reduces HIF-1a and VEGF levels in lung
MTA1 has been reported to modulate the stability of HIF-1a
through deacetylation by the MTA1/HDAC complex [6]. In addition to this, real-time PCR and Western blot analysis results
indicated that MTA1 also correlates well with other lung development-related factors such as VEGF, AQP5, SPB, and b-catenin
(Figure 6A, 6B). To investigate the regulatory role of MTA1 on
the generation of pulmonary capillaries via HIF-1a stabilization,
we examined the effect of MTA1 on the status and gene expression of HIF-1a and VEGF in cell models. As expected, MTA1
overexpression in both 293T and MLE-12 cells led to increased
expression of HIF-1a and VEGF compared to the control vector (Figure 6C), which was consistent with the increased HIF1a and VEGF mRNA levels (Figure 6D). These findings suggest
that MTA1 expression stabilizes HIF-1a, possibly via deacetylation. This, in turn upregulates the downstream expression of
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MTA1 is a component of NuRD, which regulates gene expression as well as protein deacetylation in association with
HDACs [20,21]. Previous studies have suggested that MTA1
enhances the stability of HIF-1a by recruiting HDAC1 in cancer cells [5] and that MTA1 enhances the expression of VEGF
by increasing the transcriptional activity of HIF-1a [6]. In general, increased MTA1 expression in cancer has been shown to
be closely associated with poor prognosis, increased tumor angiogenesis, and increased migration and metastasis [4,22–24].
However, cellular motility also plays a significant role in a variety of normal biological functions. For example, Li et al. have
shown that MTA1 is abundantly expressed in the lungs of
mice [2]. The underlying basis of the role of MTA1 in angiogenesis includes its upregulation under hypoxic conditions and stabilization of HIF-1a by promoting its MTA1/HDAC1-dependent
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the lungs. However, regulation of HIF-1a protein stability by
MTA1 within the lungs was previously unknown.

Newborn
mortality

To understand the effect of MTA1 deficiency on the formation of pulmonary alveolar capillaries and the expression of
HIF-1a, we investigated the functional consequences of MTA1
deficiency in the lungs of MTA1-KO mice. We observed that
MTA1 was expressed at high levels in murine lung tissue and
its depletion resulted in reduced VEGF and HIF-1a levels, fewer pulmonary alveolar capillary beds, increased infant mortality, and retarded growth. These data suggest that MTA1 promotes the formation of pulmonary capillaries by deacetylating
HIF-1a and, subsequently, modulating HIF-1a stability, increasing downstream VEGF expression, and inducing angiogenesis.

Pulmonary arterial
hypertension

VEGF

Pulmonary
capillaries

Figure 7. A correlation between the expression of MTA1 and HIF1a in the lungs. MTA1 is an active angiogenic regulator
that deacetylates HIF-1a. The MTA1- HIF-1a axis feed
into VEGF expression and the formation of pulmonary
capillaries.

deacetylation on lysine 532 [5]. HIF1 is also fundamental to
glycolysis, erythropoiesis, angiogenesis, and the prevention of
apoptosis in response to low oxygen pressure, which enables
cellular adaptation and survival in extreme conditions [25,26].
HIF-1a activity appears to depend largely on the availability of HIF-1a with a shorter half-life [5]. Regulation of HIF-1a
availability appears to occur predominantly at the post-translation level via protein stabilization. VEGF, one of the HIF-1a
primary targets, has been demonstrated to be involved in the
pathogenesis of various lung diseases, such as bronchial pulmonary dysplasia, acute lung injury, emphysema, and pulmonary hypertension [13]. In this context, hypoxia is one of the
strongest activators of VEGF expression [27–29]. Taken together, MTA1, HIF-1a, and VEGF are all related to oxygen supply,
making their expression and function potentially essential in

Conclusions
In summary, this study identified a correlation between the
expression of MTA1 and HIF-1a in the lungs, in which MTA1
is an active angiogenic regulator responsible for deacetylating
HIF-1a. The MTA1/HIF-1a axis then affects VEGF expression
and the formation of pulmonary capillaries (Figure 7). These
data enhance our understanding of MTA1 function during development and suggest that MTA1 may be a potential therapeutic target, providing new avenues for the diagnosis and
treatment of related pulmonary diseases.
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